ELIZABETH MARION JAFFEE

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Cytokine gene-modified cell-based cancer vaccines
    R Todd Reilly
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Methods Mol Med 69:233-57. 2002
  2. ncbi request reprint Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation
    E M Jaffee
    Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Clin Oncol 19:145-56. 2001
  3. ncbi request reprint Chemotherapy: friend or foe to cancer vaccines?
    L A Emens
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231, USA
    Curr Opin Mol Ther 3:77-84. 2001
  4. ncbi request reprint Focus on pancreas cancer
    Elizabeth M Jaffee
    The Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cancer Cell 2:25-8. 2002
  5. pmc Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
    Lukas W Pfannenstiel
    Department of Oncology, Sidney Kimmel Cancer Center, Division of Immunology, Johns Hopkins University, USA
    Cell Immunol 263:79-87. 2010
  6. ncbi request reprint HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice
    Matthew E Wolpoe
    Department of Otolaryngology Head and Neck Surgery, Graduate Program in Immunology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Immunol 171:2161-9. 2003
  7. ncbi request reprint Cytokine modified tumor vaccines
    Todd D Armstrong
    Bunting Blaustein Cancer Research Building, Room 4M86, Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, MD 21231, USA
    Surg Oncol Clin N Am 11:681-96. 2002
  8. pmc Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs
    Peter S Kim
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 4M86, Baltimore, Maryland 21231, USA
    J Clin Invest 118:1700-11. 2008
  9. pmc Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:5911-8. 2009
  10. ncbi request reprint Cancer vaccines in combination with multimodality therapy
    Leisha A Emens
    The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90 Baltimore, Maryland 21231 1000, USA
    Cancer Treat Res 123:227-45. 2005

Research Grants

Collaborators

Detail Information

Publications40

  1. ncbi request reprint Cytokine gene-modified cell-based cancer vaccines
    R Todd Reilly
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Methods Mol Med 69:233-57. 2002
  2. ncbi request reprint Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation
    E M Jaffee
    Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Clin Oncol 19:145-56. 2001
    ..To determine its safety and ability to induce antitumor immune responses, we conducted a phase I trial in patients with surgically resected adenocarcinoma of the pancreas...
  3. ncbi request reprint Chemotherapy: friend or foe to cancer vaccines?
    L A Emens
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231, USA
    Curr Opin Mol Ther 3:77-84. 2001
    ..These interactions will require thorough preclinical evaluation to maximize the clinical impact of this type of therapeutic cancer vaccine...
  4. ncbi request reprint Focus on pancreas cancer
    Elizabeth M Jaffee
    The Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cancer Cell 2:25-8. 2002
  5. pmc Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
    Lukas W Pfannenstiel
    Department of Oncology, Sidney Kimmel Cancer Center, Division of Immunology, Johns Hopkins University, USA
    Cell Immunol 263:79-87. 2010
    ..Finally, PTX treatment results in enhanced antigen-specific, IFN-gamma-secreting CD8(+) T cells in vivo. Thus, administration of PTX with a tumor vaccine improves T cell priming through enhanced maturation of DC...
  6. ncbi request reprint HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice
    Matthew E Wolpoe
    Department of Otolaryngology Head and Neck Surgery, Graduate Program in Immunology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Immunol 171:2161-9. 2003
    ..Collectively, these observations suggest that similarly increased efficacy could be obtained by combining neu-targeted vaccination and neu-specific Abs such as trastuzumab (Herceptin) in patients with neu-expressing cancers...
  7. ncbi request reprint Cytokine modified tumor vaccines
    Todd D Armstrong
    Bunting Blaustein Cancer Research Building, Room 4M86, Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, MD 21231, USA
    Surg Oncol Clin N Am 11:681-96. 2002
    ..Most clinical trials using genetically modified tumor vaccines have shown immunological responses (DTH), but few clinical responses. Certain chemotherapeutic agents may enhance the immune effects of genetically modified tumor vaccines...
  8. pmc Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs
    Peter S Kim
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 4M86, Baltimore, Maryland 21231, USA
    J Clin Invest 118:1700-11. 2008
    ..This multimodality attack on the same tumor antigen may have the potential to overcome tolerance to self antigens and weaken the immunosuppressive networks within the tumor microenvironment...
  9. pmc Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:5911-8. 2009
    ..We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer...
  10. ncbi request reprint Cancer vaccines in combination with multimodality therapy
    Leisha A Emens
    The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90 Baltimore, Maryland 21231 1000, USA
    Cancer Treat Res 123:227-45. 2005
  11. pmc Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma
    Ihid C Leao
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Transl Sci 1:228-39. 2008
    ....
  12. ncbi request reprint Leveraging the activity of tumor vaccines with cytotoxic chemotherapy
    Leisha A Emens
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Cancer Res 65:8059-64. 2005
    ....
  13. pmc Cellular vaccine approaches
    Dung T Le
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St, Bunting Blaustein Cancer Research Building, Room 407, Baltimore, MD 21231, USA
    Cancer J 16:304-10. 2010
    ....
  14. ncbi request reprint Immunotherapy for pancreatic cancer - science driving clinical progress
    Dan Laheru
    Department of Medical Oncology, Room G89, Baltimore, Maryland 21231 1000, USA
    Nat Rev Cancer 5:459-67. 2005
    ..Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials...
  15. pmc Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response
    Anne M Ercolini
    Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Exp Med 201:1591-602. 2005
    ....
  16. ncbi request reprint Augmenting the potency of breast cancer vaccines: combined modality immunotherapy
    Leisha A Emens
    Department of Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Breast Dis 20:13-24. 2004
    ..Combined modality immunotherapies should maximize the potency of the antitumor immune response, thereby improving the outcome of breast cancer therapy...
  17. ncbi request reprint To live or not to live: that depends on GAGE?
    Leisha A Emens
    Departments of Oncology, The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
    Cancer Biol Ther 1:388-90. 2002
  18. ncbi request reprint Toward a breast cancer vaccine: work in progress
    Leisha A Emens
    Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Oncology (Williston Park) 17:1200-11; discussion 1214, 1217-8. 2003
    ....
  19. ncbi request reprint Cancer vaccines: an old idea comes of age
    Leisha A Emens
    Departments of Oncology, The Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland 21231 1000, USA
    Cancer Biol Ther 2:S161-8. 2003
    ....
  20. ncbi request reprint Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine
    Xianzheng Zhou
    Division of Immunology and Hematopoiesis, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Cancer Res 65:1079-88. 2005
    ....
  21. ncbi request reprint Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine
    Dan Laheru
    The Sidney Kimmel Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Methods Mol Med 103:299-327. 2005
    ..Without knowledge of specific antigen targets, the whole tumor cell represents the best source of immunizing antigens. This chapter will focus on the development of whole tumor cell vaccine strategies for pancreas cancer...
  22. ncbi request reprint Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology
    Dan A Laheru
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Bunting Blaustein Cancer Research Building, Room 4M07, 1650 Orleans Street, Baltimore, MD 21231, USA
    Mol Cancer Ther 4:1645-52. 2005
    ..We outline here a paradigm for early-stage clinical development of immunotherapy combinations that use vaccines to drive tumor antigen-specific responses while simultaneously targeting immune regulatory pathways...
  23. ncbi request reprint Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens
    Josef Mautner
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Int J Cancer 115:752-9. 2005
    ..These experiments show that a dual Th1/Th2, MHC class II-restricted T-helper-cell response against diverse shared tumor antigens has been elicited in this patient...
  24. doi request reprint Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus setting
    Tomoharu Miyashita
    Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Dig Dis Sci 53:2858-67. 2008
    ..We developed and evaluated a GM-CSF whole-cell tumor vaccine for esophageal cancer...
  25. ncbi request reprint A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
    Elizabeth A Manning
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 13:3951-9. 2007
    ....
  26. ncbi request reprint OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen
    Satoshi Murata
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Immunol 176:974-83. 2006
    ..These studies highlight the increased efficacy of OX40 costimulation when combined with a GM-CSF-secreting vaccine, and define a new role for OX40 costimulation of CD8+ T cells in overcoming tolerance and boosting antitumor immunity...
  27. pmc Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients
    Amy Morck Thomas
    Department of Oncology, The Sidney Kimmel Cancer Center at Johns Hopkins, The Bunting Blaustein Cancer Research Bldg, Rm 4M07, 1650 Orleans St, Baltimore, MD 21231, USA
    J Exp Med 200:297-306. 2004
    ..These results provide the first direct evidence that CD8 T cell responses can be generated via cross-presentation by an immunotherapy approach designed to recruit APCs to the vaccination site...
  28. ncbi request reprint Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells
    Xianzheng Zhou
    Division of Immunology and Hematppoiesis, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Hum Gene Ther 14:1089-105. 2003
    ..These results will have significant implications for the study of T-cell biology and for the improvement of clinical gene therapies of acquired immune deficiency syndrome (AIDS) and cancer...
  29. ncbi request reprint Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting
    Tomoharu Miyashita
    Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    J Gastrointest Surg 12:2-7; discussion 7-9. 2008
    ..We developed a granulocyte-macrophage-colony-stimulating factor (GM-CSF) tumor vaccine for esophageal cancer. We evaluated the effectiveness of the vaccine as a prevention option in a surgical reflux rat model of esophageal cancer...
  30. pmc Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene
    Sian Jones
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Baltimore, MD 21231, USA
    Science 324:217. 2009
    ..These results illustrate that complete, unbiased sequencing of protein-coding genes can lead to the identification of a gene responsible for a hereditary disease...
  31. pmc SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer
    Amanda Blackford
    Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 15:4674-9. 2009
    ..Recently, the majority of protein coding genes were sequenced in a collection of pancreatic cancers, providing an unprecedented opportunity to identify genetic markers of prognosis for patients with adenocarcinoma of the pancreas...
  32. pmc Genetic mutations associated with cigarette smoking in pancreatic cancer
    Amanda Blackford
    Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 69:3681-8. 2009
    ..Pancreatic carcinomas from cigarette smokers harbor more mutations than do carcinomas from never smokers. The types and patterns of these mutations provide insight into the mechanisms by which cigarette smoking causes pancreatic cancer...
  33. pmc Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
    Sian Jones
    Sol Goldman Pancreatic Cancer Research Center, Ludwig Center and Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 321:1801-6. 2008
    ..Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis...
  34. ncbi request reprint Pancreatic cancer
    Theresa Pluth Yeo
    Departments of Surgery, Oncology, Pathology and Medicine Johns Hopkins Medical Institutions Baltimore, Maryland, USA
    Curr Probl Cancer 26:176-275. 2002
  35. pmc Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin
    Raffit Hassan
    Morphotek Inc, 210 Welsh Pool Road, Exton, PA, USA
    Cancer Immun 7:20. 2007
    ..We have in fact initiated a Phase I clinical study enrolling patients with mesothelin-positive pancreatic, mesothelioma, non-small cell lung and ovarian cancers...
  36. ncbi request reprint Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse
    Reshma Singh
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Immunol 175:3663-73. 2005
    ..monocytogenes-based HER-2/neu vaccines in a murine model of breast cancer and also that the immunogenicity of self-Ags can be increased by fusion to LLO and delivery by L. monocytogenes revealing subdominant epitopes...
  37. ncbi request reprint Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo
    Stephan R Scheffer
    Department of Gastroenterology, Medizinische Hochschule Hannover, Hannover, Germany
    Int J Cancer 103:205-11. 2003
    ..In contrast, necrotic cell vaccines attracted a strong local macrophage response. Our data clearly demonstrate that only apoptotic tumor cell vaccines induce a potent antitumor immune response...
  38. ncbi request reprint Cancer immunologists and cancer biologists: why we didn't talk then but need to now
    George C Prendergast
    Cancer Cell Signaling Laboratory, Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096, USA
    Cancer Res 67:3500-4. 2007
    ....
  39. ncbi request reprint Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms
    Sara Gandini
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Cancer Epidemiol Biomarkers Prev 14:1908-16. 2005
    ..The hyperactive immune system of allergic individuals may, therefore, in some way lead to increased surveillance and protect against pancreatic cancer development...
  40. pmc Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice
    Timothy P Moran
    Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA
    Vaccine 25:6604-12. 2007
    ..These findings provide the rationale for future evaluation of VRP-DC vaccines in the clinical setting...

Research Grants17

  1. Chemotherapy plus vaccine for metastatic breast cancer
    Elizabeth Jaffee; Fiscal Year: 2005
    ..In addition, characterization of breast tumor antigens may lead to the development of recombinant vaccines that can more efficiently activate antitumor immunity...
  2. IDENTIFICATION OF CD8+ T CELL TARGETS ON RENAL CANCER
    Elizabeth Jaffee; Fiscal Year: 2004
    ..abstract_text> ..
  3. ALLOGENIC PANCREATIC TUMOR VACCINE CELL LINE
    Elizabeth Jaffee; Fiscal Year: 2003
    ..g. breast and prostate). In addition, characterization of pancreatic tumor antigens may lead to the development of recombinant vaccines that can more efficiently activate antitumor immunity. ..
  4. Tolerance mechanisms regulating the complete HER-2/neu CD+8 T cell repertoire
    ELIZABETH MARION JAFFEE; Fiscal Year: 2010
    ..Specifically, we will evaluate a number of mechanisms that may differentially regulate low versus high avidity T cells including: regulatory T cells, T cell signaling pathways, and post-transcriptional regulation. ..